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Shared decision making – rhetoric and reality: women’s experiences and 
perceptions of adjuvant treatment decision-making for breast cancer 
 
Abstract 
This interview-based study uses phenomenology as a theoretical framework and 
thematic analysis to challenge existing explanatory frameworks of shared decision 
making (SDM); in an exploration of women’s experiences and perceptions of SDM for 
adjuvant treatment in breast cancer. Three themes emerged: i) women’s desire to 
participate in SDM, ii) the degree to which SDM is perceived to be shared, and iii) to 
what extent are women empowered within SDM. Studying breast cancer patients’ 
subjective experiences of adjuvant treatment decision-making provides a broader 
perspective on patient participatory role preferences and doctor-patient power dynamics 
within SDM for breast cancer. 
Key words 
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phenomenology. 
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Introduction 
Health literature over the past 40 years has reported changes in the ideology and 
practice of medical decision-making. In between the ‘paternalistic’ and ‘informed 
patient’ models stands a consumer or ‘shared’ model of decision-making, which in 
recent years has become more explicit in modern healthcare systems. This cultural shift 
in decision-making is in response to changes in the ethical notions of patients’ rights to 
be fully informed and autonomous participants in their treatment decisions 
(Breitsameter, 2010; Siminoff et al, 2010). Sharing decisions, as opposed to health 
professionals making decisions on patients’ behalves, has gained prominence in 
healthcare policy (Department of Health, 2010; O’Connor et al, 2007). “No decision 
about me without me” (Coulter and Collins, 2011; Department of Health, 2010) 
promotes a more patient-centred healthcare system through the practice of shared 
decision making (SDM), which is endorsed by UK clinical guidelines (NICE, 2004, 
2012). SDM, originally proposed by Charles et al (1997), is defined as an interactional 
process between the health professional and patient, characterised by mutual 
engagement and participation, in which information is shared in a context that 
acknowledges the different values and preferences of both parties (Elwyn et al, 2012; 
Elwyn and Charles 2001; Towle and Godolphin, 1999).  
The concept of SDM has been suggested as the prevailing approach for doctor-patient 
treatment decision-making in breast cancer (Chewning et al, 2012), and is shown 
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largely to be associated with adjuvant rather than surgical treatment (Mandleblatt et al, 
2006) Women with breast cancer can face several challenging and important 
preference-sensitive decisions (i.e. when more than one treatment option is available 
and there is no “best” choice for everyone). Decision-making for adjuvant treatment can 
often be difficult for breast cancer patients due to the combination of several therapeutic 
options available (e.g. chemotherapy, radiotherapy, hormone therapy, or no additional 
therapy). Decision-making can also be complex as the choice depends largely on the 
estimated risk of relapse. The degree of benefit, in terms of disease-free survival and 
overall survival, is also uncertain.  
A small proportion of breast cancer patients choose either a completely ‘passive’ or 
completely ‘active’ role in decision-making (Elkin et al, 2007; Say et al, 2006; Vogel et 
al, 2008). The past decade has seen an increase in breast cancer patients’ preferences for 
more ‘collaborative’ decision-making roles (Brown et al, 2012; Deber et al 2007; 
Hubbard et al, 2008; Sabo et al, 2007; Singh et al, 2010; Tariman et al, 2010), with 
SDM shown to improve breast cancer patients’ quality of life and satisfaction with 
treatment (Anderson et al, 2009; Ashraf et al 2013; Joosten et al, 2008; Lam et al, 2014; 
Mandelblatt et al, 2006; Sabo et al, 2007). However, there is a paucity of research about 
the use of SDM in breast cancer care. Charles et al (2004) reported a cross-sectional 
study exploring oncologists’ perceived barriers and facilitators to implementing SDM in 
breast cancer. Key barriers identified were lack of time, information and patient 
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unwillingness to participate, and facilitators included patients’ emotional readiness, 
support, information and trust in their oncologists. Similarly, Mandelblatt et al (2006) 
conducted surveys with older women with breast cancer and oncologists to describe 
determinants of SDM, and to evaluate whether SDM is associated with treatment 
patterns and outcomes of care. They showed greater association between SDM and 
adjuvant treatment, and improved patient short-term satisfaction with treatment. While 
both of these studies are useful in demonstrating the effectiveness and benefits of SDM 
in breast cancer care, they give a limited view of the SDM experience itself. As SDM is 
a subjective interaction between two people, more critical approaches and qualitative 
methods are needed to examine the decision-making processes for women. The missing 
component within the existing literature on SDM and breast cancer is how women 
conceptualise SDM, and the extent to which they perceive decision-making as being 
shared. A unique opportunity exists to highlight SDM processes as experienced and 
viewed by patients in this clinical speciality. To address this gap, this paper explores 
women’s experiences and perceptions of SDM for adjuvant treatment in breast cancer. 
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Method 
Design 
Semi-structured interviews were conducted with a purposive, homogeneous sample of 
women, with resulting transcripts analysed using thematic analysis (Braun and Clark, 
2006). The study is informed by descriptive phenomenology (Husserl, 1970) as an ideal 
theoretical framework and methodology for a deeper understanding and insightful 
description of the ‘lived’ experience. Phenomenology, as a discipline, is rooted within 
the principle that the most basic human ‘truths’ are only accessible through the 
subjective view of the individual experiencing reality (Merleau-Ponty, 2012). In line 
with a critical health approach, phenomenology is argued to be a reflection on conscious 
experience rather than subconscious motivation, and is designed to uncover the essential 
invariant features of that experience (Jopling, 1996).  Descriptive phenomenological 
research places emphasis on the ‘pure’ description of people’s experiences, by 
describing meanings with depth and richness at the descriptive semantic level. The 
purpose of this study was to embark on an intense analysis of the descriptions and 
‘lived’ experiences of SDM for adjuvant treatment, as provided by women with breast 
cancer.  
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Participants and recruitment 
Twenty women aged >18 years (mean age 57, range 40-73), who had undergone 
adjuvant treatment following breast cancer surgery, in a National Health Service (NHS) 
hospital outpatient breast cancer unit, were recruited. The women had completed all 
adjuvant treatment two years prior to being approached to participate, to help ensure 
levels of relative physical and emotional stability following diagnosis. Supplementary 
file 1 provides additional information on participant treatment profiles and 
demographics.  
Potential participants were identified through screening of patient records by the breast 
cancer nurse specialists. A sample of 50 women who attended the breast cancer 
adjuvant treatment follow-up clinic were first told about the study by their oncologist, 
and invited to take part. Those who agreed received written information about the study 
and were asked for written consent. Twenty (40%) women agreed to participate, nine 
(18%) declined, and the remaining 17 (34%) did not respond. The main reasons given 
for non-participation were time constraints. No further attempts were made to recruit 
more participants, as the researchers determined that thematic saturation was reached 
and no additional information or variations of a given theme in the data was 
forthcoming (Chamberlain, 1999; Miles and Huberman, 1994). Ethical approval was 
granted by the local NHS Research Ethics Committee, and guidelines prescribed by The 
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British Psychological Society (2014) were used to inform ethical practice throughout 
the study. 
Interviews 
Semi-structured interviews were conducted on a face-to face basis at the outpatient 
breast unit. All women were aware that the interviewer was an academic researcher 
rather than a health care professional. Interviews lasted between 45 and 60 minutes, 
were audio recorded and transcribed verbatim. Pseudonyms were used in all notes, 
transcripts and analyses. Practical recommendations and guidelines for interviews in 
qualitative research were observed (Howitt, 2010; Smith, 2008), and best practice 
regarding data handling was followed (Department of Health, 2005).  
A schedule of broad open-ended questions provided a framework to guide discussions 
about women’s experiences and perceptions of breast cancer adjuvant treatment 
decision-making in general, and more specifically on SDM. Questions about adjuvant 
treatment for breast cancer assessed women’s knowledge about the quality, quantity and 
sources of information received. The women were also asked about their adjuvant 
treatment choices and their level of involvement in the decision-making process. Some 
questions focused specifically on their understanding of SDM, for example, “what does 
SDM mean to you?” It is important to clarify that the women were never given a 
definition of SDM; rather, they were asked an open-ended question and given the 
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opportunity to take the question in any direction they wanted (Clandinin and Connelly, 
2000). The women were also asked about their relationship with the oncologists, 
including experiences of doctor-patient interaction, disagreement and partnership. All 
questions in the schedule were formulated to facilitate the women’s descriptions of their 
own experiences of decision-making, while exploring in-depth issues related to doctor-
patient relationships and communication, patient participation, and the process of SDM.  
Data analysis 
Braun and Clarke’s (2006) thematic analysis approach was employed to identify themes 
relating to women’s understandings and encounters of SDM. Analysis was inductive, 
whereby concepts and categories emerge from the data. Transcripts were read several 
times by NM to gain familiarisation of each individual’s account, and initial patterns 
were noted. The data was subjected to ‘open coding’, involving a close reading of each 
transcript and the division of portions of text into specific units of meaning (codes). 
This involved identifying where and how patterns occur and searching for connections 
across the data. Following the production of an initial set of codes, a thematic table 
(supplementary file 2) was produced to present the main themes. Themes were 
identified by collating components of ideas or experiences (codes) together, which often 
appear meaningless when viewed alone, to form a more detailed account of the 
women’s experiences and perceptions of SDM. A second review was undertaken by SS 
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to assist with the contextualisation of the themes, as reflected in the findings, and to 
cross-examine all themes identified. Themes were then named. Reflexive commentary 
during the analytical stages was engaged by both authors through the use of a reflexive 
diary, as a measure of quality assurance (Willig, 2008).  
 
Results 
Thematic analysis revealed three main themes across all transcripts: 1) women’s desire 
to participate in SDM, 2) the degree to which SDM is perceived to be shared, and 3) to 
what extent are women empowered within SDM. These themes provide broader 
subjective insights about breast cancer patients’ experiences and perceptions of SDM for 
adjuvant treatment. 
Theme 1: women’s desire to participate in SDM  
All of women in the study illustrated an ‘active’ role, in that they described a sense of 
personal control or ownership over the extent to which they desired to participate in 
decision-making. In describing their desired degree of involvement, the women 
demonstrated contrasting participatory roles preferences. The majority displayed an 
‘active-collaborative’ role, where they preferred to be involved in treatment decision-
making and to participate in SDM, whilst a minority illustrated an ‘active-passive’ role 
by choosing to disengage from treatment decision-making and the process of SDM.  
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Most of the women who demonstrated an ‘active-collaborative’ role, wanted to be 
informed, and were keen to discuss their treatment options and share their opinions. 
They actively chose to participate in decision-making, and preferred to make their 
treatment decision in collaboration with the oncologist through the process of SDM:  
I wanted to take part in decision-making, have discussions and ask questions about the 
different treatments so I could better understand my options. But when it actually came 
down to deciding which treatment was best for me, I decided to share that task with my 
oncologist. I think it’s a difficult one to make on your own and I am happy I decided to 
make it with my doctor. I felt much supported that way. Choosing to share the 
responsibility of decision-making made the task so much easier. [Jane] 
Jane describes her ‘active’ desire to be involved in treatment decision-making. She 
explains the importance of information and increased knowledge about her treatment 
options, which she was able to obtain through her decision to engage in discussions with 
the oncologist and ask questions. However, she indicates that due to the complexity of 
decision-making, and in order to make the “best” decision, she personally opted for a 
‘collaborative’ and shared approach to decision-making. By choosing to participate in 
SDM with the oncologist, she was satisfactorily able to share the responsibility of the 
task, and receive the support needed to make an “easier” decision. 
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Other women actively choose to remain ‘passive’ in decision-making and showed little 
interest to participate in SDM:  
When I got diagnosed, I was given a big information booklet which I didn’t look at. I 
had so many opportunities to have a say, to discuss the options with my oncologist and 
be a part of decision-making process, but I didn’t want to. I didn’t want to absorb any 
knowledge that could worry me more. [...]I chose not to be involved in decision-making 
full stop, let alone share decision-making. I totally avoided having those conversations 
together, and just let him decide. [Charlotte] 
Charlotte illustrates an ‘active- passive’ participatory role. She explains that even 
though she was presented with many opportunities to be involved or to collaborate in 
treatment decision-making with the oncologist, her ‘active’ preference was to remain 
‘passive’. For some women, similar to Charlotte who displayed ‘active-passive’ traits, 
increased treatment knowledge was regarded as an emotional burden, adding further 
fear and anxiety. Instead they took a defensive approach to decision-making, where 
ignorance is bliss. Charlotte demonstrates this further in her account, as she describes 
how her main goal was to restrict the amount of information acquired, through avoiding 
shared conversations with the oncologist. She withdrew herself from decision-making 
and instead situated the oncologist as the decision-maker. Her ‘passive’ participatory 
role preferences meant that participation in SDM was of no significance or appeal to 
her. 
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Theme 2: the degree to which SDM is perceived to be shared  
The majority of women showed good understanding of SDM, and identified two 
characteristics associated with the process: ‘two-way interaction’ and ‘information 
acquisition’. The process of SDM was often described by some of the women in relation 
to key subjective terms, such as equal, mutual, and sharing. However, there appeared to 
be a discrepancy between how they described these SDM particulars, and how they 
represented the process of SDM in reality. 
For some of the women who had to decide over several adjuvant treatment options, 
SDM was largely perceived as a mutual or equal process. They reported that SDM is 
most feasible through doctor-patient collaboration, which involves sharing of ‘two-way 
interaction’ and ‘information acquisition’:  
For me, shared decision making was a discussion. For example, if the consultant 
suggests a certain treatment would be the best route for me to go down, but I wasn’t 
sure, then we would have a mutual conversation together to come to an informed 
agreement or decision. So shared decision making is an equal 50/50 process. I ask, he 
explains. I query, and he suggests. Through this back and forth process together we 
shared information and reached a decision. [Judy]  
Judy refers to the importance of ‘two-way interaction’ and ‘information acquisition’, in 
the face of decisional uncertainty. She defines SDM as “50/50”, “equal” and reciprocal 
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process between doctor-patient, where the oncologist’s purpose is to identify and explain 
information, and the patient’s is to query and share their concerns. This perceived 
“mutual” process of two-way communication and information sharing is viewed by 
Judy as a seemingly equal weighted route towards decision-making. It appears that 
although, on the surface, Judy perceives decision-making to be equal, it is far from 
constructed as a symmetrical process in practice. There is no indication that Judy 
“explains or suggests”, or that the oncologist “asks or queries”. There appears to be 
little “50/50” balance in terms of ‘information acquisition’ and ‘two-way interaction’ as 
far as decision-making. 
Understanding of SDM was also evident in some of the women who were not given a 
choice in their adjuvant treatment course. Most of these women valued having full 
understanding of their treatment, as determined by the oncologist. They too made a 
reference to the terms sharing and ‘information acquisition’ as key components 
associated with SDM: 
I wasn’t given a decision to make. I was told I had to have chemotherapy because of my 
cancer grade. But not having a choice didn’t bother me. I was happy because I was well 
informed, and I think that’s really important. [...]When I saw the oncologist, he 
explained everything to me about the treatment. For me, shared decision making is 
being explained what is going to happen. By the doctor sharing all his knowledge with 
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me, and allowing me to know all I needed to know, that’s what makes it a shared 
decision. [Paula] 
Paula’s treatment was determined by the oncologist due to her cancer type. This was not 
viewed as problematic, as it appears that the process of explanation maximised her 
satisfaction with the treatment. Later in her account, Paula defines SDM as a process of 
‘information acquisition’ which involves the oncologist “sharing” all available 
information about her treatment. In Paula’s case, the oncologist is therefore sharing 
everything on a decision that has already been made for her. It appears that although the 
oncologist is “allowing” her to be informed, there is no indication of ‘information 
acquisition’ being reciprocated by the oncologist. The process appears to be one-way, 
with no evidence of Paula being allowed to share information (i.e. her views and values) 
with the oncologist. With a lack of ‘two-way interaction’, how would the oncologist 
know how much information Paula “needs” to know? This account reflects a lack of 
two-way processes and sharing in decision-making. 
Theme 3: to what extent are women empowered within SDM 
Some of the women’s accounts brought insight into the roles and positions that women 
and oncologists take during SDM. Many held an objective view of a perceived 
discrepancy in doctor-patient power relations, which appeared to discourage patient 
empowerment and SDM in practice. 
15 
 
For some of the women their oncologist was viewed and labelled as a problem solver 
with a duty of care. There was a strong belief that the oncologists had more discretion 
over decision-making due to their hierarchical status and ascribed role as a medical 
healer. This expedited an imbalance in doctor-patient power-relations for SDM:  
It was hard to share the decision. I always put all my confidence and trust into the 
doctors. I believe in these people and their role as medical professionals and decision-
makers. I mean, everyone knows that if there is something medically wrong with you, 
it’s the doctor’s responsibility to put you right. [...] I remember he said to me “It’s my 
job as your doctor to give you the best possible chance of survival”.  [Sandy] 
Sandy’s account illustrates the differential roles and power struggles that exist in doctor-
patient relationships. She refers to her oncologist as the “decision-maker”, and an 
authoritative “professional” with healthcare responsibilities. On the contrary, she 
regards herself (i.e. the patient) as a spectator of care and someone who puts trust in 
their oncologist’s role. She defends this view by illustrating it as a societal attitude and 
expected norm of behaviour. Later in her account, she describes how the oncologist 
reinforces this normative view and her subjective assessment of the differential roles, by 
emphasising his “job” as a medical healer, linked to maximising patient “survival”. 
Sandy explains that an objective disparity in doctor-patient roles, arguably, makes SDM 
difficult to achieve.  
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As well as perceived discrepancy in roles, some of the women also described an 
objective discrepancy in medical knowledge and skills between the doctor and patient, 
which became the product of women’s detachment from SDM: 
 I just have basic knowledge of breast cancer. I’m a believer that if you’re the health 
professional then you obviously know and can decide what is best. Cancer isn’t like a 
cold...it requires medical expertise and skills to treat. So I was in no position to make 
any big decisions. [...]It’s the doctor’s call. He’s the expert, which made it difficult to 
share any decision. [Louise] 
Louise describes how she felt unqualified to make any important treatment decisions. 
She heightens the doctor-patient power imbalance by referring to her normative belief 
that the oncologist is “the expert” and the person who “knows and decides what is best” 
for her. This arguably repositions Louise, in relation to the oncologist, as someone of 
“no position” and less power, which further reinforces any perceived role differentials. 
Towards the end of Louise’s account, she explains how such objective disparity in 
doctor-patient expertise left very little room for SDM to occur.  
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Discussion 
This study confirms previous findings that women with breast cancer can have 
identifiable participatory role preferences in decision-making (Elkin et al, 2007; Say et 
al, 2006; Vogel et al, 2008), with the majority preferring a ‘collaborative’ approach 
(Brown et al, 2012; Deber et al 2007; Hubbard et al, 2008; Sabo et al, 2007; Singh et al, 
2010; Tariman et al, 2010). In contract to these studies, which illustrate ‘active’ and 
‘passive’ roles dichotomously, our findings suggest that both of these roles can be 
presented as two poles of dialectic. For example, choosing to be ‘passive’ was an 
‘active’ decision for some of the women in our study. Our findings introduce the terms 
‘active-passive’ and ‘active-collaborative’, and is the first to add new knowledge 
regarding the contribution of these roles to women’s encounters of SDM for adjuvant 
treatment in breast cancer.  
The women all described their participation in decision-making with personal sense of 
‘active’ ownership, which is, as one that they felt was right for their participatory role 
preference. Those who actively chose to remain ‘passive’ in decision-making (‘active-
passive’) supported a ‘paternalistic’ model of decision-making, in comparison to the 
majority of women who actively chose to collaborate and engage in SDM with their 
oncologist (‘active-collaborative’). This suggests that while a ‘collaborative’ approach to 
decision-making is popular and may be desirable, it is by no means universally held by 
all women with breast cancer. The women showed mixed attitudes towards participation 
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in SDM, and this suggests that SDM is not a fixed preference in this clinical context. 
Despite the opportunities presented by oncologists for ‘active-passive’ women to engage 
in SDM, many chose to remain submissive as it took the burden of decision-making 
away from them. Converging with other evidence, one reason identified was that they 
wanted to avoid negative information about their prognosis (Kvåle and Bondevik, 2008).  
The implications for practice drawn from these findings indicate that even in today’s 
patient-centred health care climate, it cannot be assumed that all women with breast 
cancer want to participate in the adjuvant treatment decisions of their breast cancer care. 
Until further research is conducted and more is known about breast cancer patients’ 
motivations regarding SDM, oncologists should be sensitive to individual patients’ role 
preferences, and to assess the extent they desire to be involved in SDM.  Oncologists 
may need training to better conceive patients’ preferences and information needs, and 
patient-centred communication skills might be useful to meet this task. 
Some of the women in this study understood the fundamental principles of SDM, and 
began to show what is regarded as valuable content within a SDM conversation i.e. 
‘information acquisition’, and how it should be managed i.e. through ‘two-way 
interaction’. These findings suggests that breast cancer patients acquire understandings 
of SDM that are aligned with UK clinical guidelines (NICE, 2004, 2012), and 
associated with literature on the frameworks of SDM (Charles et al, 1997; Elwyn et al, 
2012; Elwyn and Charles 2001; Towle and Godolphin, 1999). Understanding of SDM 
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was also apparent for some of the women who were not given treatment choice. This 
suggests that breast cancer patients’ subjective experience of SDM is not dependent on 
whether there are adjuvant treatment options available.  
In describing the two characteristics of SDM, both groups of women (with or without 
treatment choice) drew particular attention to subjective terms, such as mutual, equal 
and sharing. Deeper critical interpretation of their subjectivity suggest that what is 
perceived as a shared process of ‘information-acquisition’ and ‘two-way interaction’, 
constituting towards an encounter of SDM, appears in reality to be a less balanced,  
asymmetrical and, even for those who are not presented with treatment options, a one-
way process.  In this clinical context, should the ultimate goal for SDM in breast cancer 
care be equality? If so, who determines what constitutes a shared or mutual decision-
making process?  In circumstances where women have no choice, should the 
oncologists have more say, or should women be supported and empowered in their 
ability to use the information acquired to contribute to the decision? Our findings draw 
attention to some of the questions and dilemmas that appear to exist in the process of 
SDM for adjuvant treatment in breast cancer. To better understand these issues and the 
mechanics of SDM during adjuvant treatment consultations, it is recommended for 
future research to take a discursive or symbolic interactionist approach to explore the 
objective conversations and’ talk-in-interaction’ between doctor-patient for SDM, as 
this is currently omitted from the existing SDM and breast cancer literature. 
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Discussions about the power dynamic involved in SDM remained at the periphery of the 
process for some of the women in this study. They cited the value of equality in SDM, 
but also alluded to the reality of the intrinsic power dynamics during SDM (Frosch et al, 
2012; Joseph-Williams et al 2014). The concept of SDM is designed to empower 
patients to become more involved in their healthcare (The Health Foundation, 2013). 
However, the findings from this study suggest that SDM for adjuvant treatment in 
breast cancer does not match this ideology. Inequality and power imbalance within 
SDM was shown to be a result of the objective discrepancy in medical expertise and 
roles between the doctor and patient. This finding adds an important dimension to 
theoretical constructions of SDM for breast cancer, as there currently appears to be a 
misalignment between the goals of oncologists and the rhetoric regarding women’s 
empowerment during adjuvant treatment decision-making. This provides momentum for 
further research to examine the relatively unexplored area of patient empowerment and 
SDM for breast cancer, as this critical aspect is often omitted in the SDM literature. It is 
a worthy recommendation for future research to explore women’s empowerment by 
applying a feminist perspective that takes power differentials in gender into account. 
The women in this study all referred to the oncologists as a male, with no mention of 
female oncologists. It would therefore be of further interest to qualitatively explore the 
impact of gender on doctor-patient relationship and SDM for breast cancer.  Until more 
knowledge arises in this area, the challenge remains to promote attitudinal change and 
21 
 
self-efficacy in women. Professional education in communication skills and training 
interventions are recommended to encourage oncologists to empower women within 
SDM. Patient education regarding doctor-patient collaborative working and patient-
centred care would also be of value. The Department of Health’s (2001) “Expert 
Patient” programme, based on the work of Lorig et al (2001) is one example of such an 
initiative.  
Limitations should be acknowledged. All women included in this study were white 
British and over the age of 40. It is recognised that women from different races, ethnic 
backgrounds and ages, especially younger women, may have different perceptions and 
experiences of SDM, or expectations of their care. The interview schedule may have 
been directive, with women probed to say the words “SDM” in describing their 
decision-making experience. The questions asked could also be criticised for being 
myopic, as the interview schedule only yielded positive evaluations of SDM and did not 
explore patients’ negative experiences or suggestions for improving the SDM process. 
This study, however, contributes to an emerging body of literature on SDM in breast 
cancer care, and is among the first to examine SDM through the theoretical framework 
of phenomenology.  It provides valuable insights into women’s experiences and 
perceptions of SDM for breast cancer adjuvant treatment. More qualitative research, 
using critical approaches, will positively contribute to advance the knowledge and 
recognition that patients and healthcare providers have on SDM for breast cancer. As 
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this paper only focuses on the adjuvant treatment stage of breast cancer, it is 
recommended for future research to explore patients’ experience of the SDM process 
for breast surgical and reconstructive treatment.  A social constructionist perspective 
would be of value for a better understanding of the broader and critical issues 
surrounding societal attitudes towards women’s bodies and breast removal, which may 
be pertinent to women’s experiences of SDM.   
 
Conclusion 
From this sample of women, the findings suggest that breast cancer patients are readily 
able to identify their preferred level of involvement in SDM. SDM was not a fixed 
preference, as desire to participate was greatest among those who displayed an ‘active- 
collaborative’ participatory role, than those who were ‘active-passive’.  
The majority of women showed understanding of SDM in line with clinical guidelines 
and existing frameworks of SDM. They described characteristics and terms associated 
with SDM, such as ‘information acquisition’, equal, and ‘two-way interaction’. 
However, their subjectivity did not equate to a ‘shared’ decision-making encounter in 
reality. Many also described an unequal power imbalance within SDM due to an 
objective discrepancy in doctor-patient knowledge and role expectations. For SDM to 
become more of a reality in the adjuvant treatment phase of breast cancer practice, 
future implementation attempts should consider these patient-reported experiences. To 
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further advance understanding of SDM for breast cancer, more qualitative research with 
critical approaches is needed to explore SDM across the whole breast cancer treatment 
trajectory, and to examine the objective process of SDM. 
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